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The incidence of liver disease progression among subjects with histologically advanced but
compensated chronic hepatitis C is incomplete. The Hepatitis C Antiviral Long-term
Treatment against Cirrhosis Trial was a randomized study of 3.5 years of maintenance
peginterferon treatment on liver disease progression among patients who had not cleared
virus on peginterferon and ribavirin therapy. Patients were followed subsequently off ther-
apy. Because maintenance peginterferon treatment did not alter liver disease progression,
we analyzed treated and control patients together. Among 1,050 subjects (60% advanced
fibrosis, 40% cirrhosis), we determined the rate of progression to cirrhosis over 4 years
and of clinical outcomes over 8 years. Among patients with fibrosis, the incidence of cir-
rhosis was 9.9% per year. Six hundred seventy-nine clinical outcomes occurred among 329
subjects. Initial clinical outcomes occurred more frequently among subjects with cirrhosis
(7.5% per year) than subjects with fibrosis (3.3% per year) (P < 0.0001). Child-Turcotte-
Pugh (CTP) score 7 was the most common first outcome, followed by hepatocellular car-
cinoma. Following occurrence of a CTP score 7, the rate of subsequent events increased
to 12.9% per year, including a death rate of 10% per year. Age and sex did not influence
outcome rates. Baseline platelet count was a strong predictor of all clinical outcomes. Dur-
ing the 8 years of follow-up, death or liver transplantation occurred among 12.2% of
patients with advanced fibrosis and 31.5% of those with cirrhosis. Conclusion: Among
patients with advanced hepatitis C who failed peginterferon and ribavirin therapy, the rate
of liver-related outcomes, including death and liver transplantation, is high, especially
once the CTP score reaches at least 7. (HEPATOLOGY 2011;54:396-405)
M
ost published data on the rate of progression of
chronic hepatitis C, except after transfusion-
associated non-A, non-B hepatitis,1 have been
derived from single-center studies, which were often small
and lacked protocol-driven systematic data collection.1-10
Based on such reports, the annual incidence of progres-
sion to hepatic decompensation in compensated cirrhosis
has been estimated to be 6% (range, 4%-8%).
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In the Hepatitis C Antiviral Long-term Treatment
against Cirrhosis (HALT-C) Trial,11,12 we enrolled
1,050 patients with histologically advanced chronic
hepatitis C who had failed to achieve a sustained viro-
logic response with peginterferon-ribavirin therapy;
subjects were assigned randomly to receive low-dose
peginterferon alfa-2a (90 lg/week) or no further treat-
ment for 3.5 years.11 Because the treated and
untreated control groups experienced similar rates of
clinical progression,12 the combined HALT-C Trial
cohort provided a unique opportunity to determine
rates of clinical progression in a large, prospectively
followed population with histologically advanced, com-
pensated chronic hepatitis C. Extension of the study
beyond the 3.5-year randomized treatment phase for
up to 8 years provided the opportunity to characterize
prospectively the course of advanced chronic hepatitis
C more comprehensively than has been possible here-
tofore. In this article, we describe the frequency and
temporal development of the major clinical outcomes
of hepatic decompensation. We also describe the se-
quential emergence of laboratory changes associated
with hepatic dysfunction and their relationship to clin-
ical outcomes.
Patients and Methods
The design of the HALT-C Trial (ClinicalTrials.gov
#NCT00006164) and results of this randomized trial
of peginterferon maintenance therapy were
described.11,12 To be eligible for the trial, adult
patients with chronic hepatitis C had to have failed to
achieve a sustained virologic response after a course of
at least 12 weeks of interferon-based therapy and have
advanced bridging fibrosis (Ishak fibrosis stage 3-4) or
cirrhosis (stage 5-6) on a baseline liver biopsy within
12 months prior to enrollment. Potential subjects were
excluded for a platelet count <50,000/mm3, absolute
neutrophil count <1,000/mm3, hematocrit level
<33%, alpha-fetoprotein level >200 ng/mL, Child-
Turcotte-Pugh (CTP) score 7, or a history of decom-
pensated liver disease or hepatocellular carcinoma
(HCC). Patients with other causes of liver disease,
uncontrolled comorbid medical (including malignan-
cies, autoimmune disorders, and immunocompromised
states) or psychiatric illnesses, or contraindications to
interferon were excluded, as were pregnant or breast-
feeding women.
Potential participants in the HALT-C Trial were
treated in a lead-in phase with peginterferon alfa-2a
(180 lg/week subcutaneously) and ribavirin (1,000-
1,200 mg/day);13 those who failed to clear hepatitis C
virus (HCV) RNA by week 20, categorized as nonres-
ponders,11,12 were randomized to 3.5 years of 90 lg/
week of peginterferon alfa-2a or to an untreated con-
trol group. Subjects with undetectable HCV RNA at
treatment week 20 were categorized as responders and
received combination treatment for 48 weeks. Res-
ponders with detectable HCV RNA after week 20
(breakthrough or relapsers) were also eligible for ran-
domization. In addition, patients failing to achieve a
sustained virologic response following peginterferon
and ribavirin treatment administered outside the
HALT-C Trial were also eligible for randomization. Of
1,730 screened subjects, 1,050 were randomized.12
Study subjects were seen in one of 10 clinical centers
at 3-month intervals through month 48 and every 6
months thereafter until October 2009.
Protocol-defined clinical outcomes included a CTP
score of 7 on two consecutive study visits 3 months
apart (6 months apart in the postrandomization
phase), variceal hemorrhage, ascites, hepatic
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encephalopathy, spontaneous bacterial peritonitis, defi-
nite HCC, or death either related or unrelated to liver
disease. For this analysis we also included liver trans-
plantation and presumed HCC as clinical outcomes.
In addition to individual clinical outcomes, we defined
three groups of clinical outcome. ‘‘Any clinical out-
come’’ was the definition used in the original HALT-C
Trial protocol and included death from any cause, pre-
sumed or definite HCC, variceal hemorrhage, ascites,
spontaneous bacterial peritonitis or hepatic encephal-
opathy. ‘‘Decompensated liver disease’’ was defined as
variceal hemorrhage, ascites, spontaneous bacterial per-
itonitis, or hepatic encephalopathy. ‘‘HCC/Decompen-
sation’’ was defined as presumed or definite HCC, as
defined,14 or decompensated liver disease. Protocol
biopsies were performed approximately 2 and 4 years
after enrollment
The stage of histologic fibrosis was interpreted
according to the Ishak score by consensus face-to-face
vote of the 10 study-site pathologists and a coordinat-
ing pathologist. For subjects in the fibrosis stratum,
progression to cirrhosis (Ishak fibrosis stage 5 or 6)
was determined. A rotating group of HALT-C Trial
investigators, masked as to identity of subject, study
site, and randomization group, reviewed every clinical
outcome to determine whether it met predefined crite-
ria. In addition, after completion of the study, a mor-
tality committee reviewed every death prior to Decem-
ber 31, 2008, again with masking of subject, site, and
randomization group, and classified the death as liver-
related or unrelated, based on predefined criteria.15
For deaths that occurred between January 1, 2009,
and October 31, 2009, the clinical site principal inves-
tigator determined whether or not the death was liver-
related. If the cause was unknown, the death was
counted as non–liver-related. Three hundred twenty-
nine (31%) patients had an outcome, 197 were fol-
lowed for 7 years without an outcome, and 298
were followed for <7 years without an outcome but
were seen in the last 6 months of the trial, which rep-
resented 79% of the study cohort. Analysis of liver
transplantation and liver-related death was also
included in the current analysis.
Determination of Laboratory Criteria for Disease
Progression. Because laboratory data were collected at
uniform intervals, we evaluated the rate of progression
of laboratory markers of liver disease progression. Prior
to analyzing laboratory data, we selected the laboratory
thresholds in the CTP score (albumin 3.5 g/dL, total
serum bilirubin 2.0 mg/dL, international normalized
ratio 1.7), as well as creatinine 1.2 mg/dL and pla-
telet count <100,000/mm3. We also used a model of
end-stage liver disease (MELD) score16 of 15.
Statistical Analyses. Statistical analyses were per-
formed at the Data Coordinating Center (New Eng-
land Research Institutes, Watertown, MA) with SAS
(release 9.1) software. Time to outcome was measured
as the number of months or years from randomization
to the date of the initial clinical outcome. For analyses
with the initial events after CTP score 7, we com-
puted time from the date of the CTP elevation to the
date of the initial clinical outcome event after the
CTP elevation. For comparison of time to clinical and
laboratory outcomes between the fibrosis and cirrhosis
strata, we performed Kaplan-Meier life-table analyses
and applied the log-rank test. Cox proportional haz-
ards models were used to estimate the relative risks of
clinical outcomes. Because outcomes occurred at rela-
tively linear rates, they are reported as annualized rates.
Outcomes were counted if they occurred within 8.0
years of randomization and before October 20, 2009.
Other than death, clinical outcomes that occurred after
liver transplantation were not counted. Annualized
rates of cirrhosis development were extrapolated from
the 2- and 4-year biopsy results.
The HALT-C Trial was approved by the institu-
tional review boards at each participating site. All
patients provided written informed consent before par-
ticipating in the trial.
Results
In the HALT-C Trial,12 1,050 study patients—622
(60%) with noncirrhotic fibrosis (Ishak stages 3-4) and
428 (40%) with cirrhosis (Ishak stages 5-6)—were
randomized to maintenance treatment or to an
untreated control group for 3.5 years and followed af-
ter the randomized phase of the trial for up to an
additional 5 years. The median duration of participa-
tion in the trial (time from randomization to first out-
come or last time known to be outcome-free) was 6.0
years (range, 0-8.7 years). Baseline characteristics of
study subjects included mean age 51 years, 71% male,
8.2% African American, estimated mean duration of
HCV infection 28 years, and mean body mass index
30 kg/m2. At baseline, levels of serum alanine amino-
transferase (ALT) were elevated in 83% (mean 2.1 
the upper limit of normal), and mean serum HCV
RNA was 6.4 log10 IU/mL. Baseline mean serum total
bilirubin (0.8 mg/dL), albumin (3.9 g/dL), and pro-
thrombin time (international normalized ratio, 1.04)
were normal.12 Mean platelet count was 165,000/
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mm3; 44.4% of patients had a platelet count
<150,000/mm3.
Clinical and Histological Outcomes. In the fibrosis
stratum, 235 clinical outcomes occurred in 122
patients with an 8-year cumulative incidence of first
outcome of 28.8% and annualized rate of 3.6% (Fig-
ure 1). In the cirrhosis stratum, 444 clinical outcomes
occurred in 207 patients with an 8-year cumulative
rate of 60.6% and annualized rate of 7.6% (difference
between strata, log-rank test, P < 0.0001). Among
patients with cirrhosis, the time to first clinical out-
come (non–liver-related deaths excluded) occurred at a
constant rate throughout the 8-year study period.
Among the fibrosis group, first outcomes occurred
infrequently during the first year but, thereafter, also
occurred at a constant albeit lower rate. Overall, the
rate of initial outcomes was similar among patients
assigned to peginterferon (5.2% per year) and the con-
trol group (5.3% per year, P ¼ 0.88); however, the
annual rate of initial outcomes was higher in the
peginterferon group than in the control group among
patients in the fibrosis stratum (4.4% versus 2.9%,
P ¼ 0.04) and slightly lower in the peginterferon
group than in the control group in the cirrhosis stra-
tum (6.6% versus 8.4%, P ¼ 0.08). In further analysis
of time to first decompensation event (ignoring CTP
score 7), the rate of 1.9% per year among patients
assigned to treatment was similar to the rate of 2.5%
per year among the control group (P ¼ 0.16). Because
liver-related outcomes were not markedly influenced
by maintenance peginterferon therapy, we combined
the peginterferon group and the control group for this
analysis. Furthermore, because outcomes occurred at a
nearly linear rate over the 8 years of study, we esti-
mated the annual incidence of individual clinical
outcomes.
Among the clinical events that constituted outcomes
in this analysis, the most frequent first outcome was
CTP 7; followed by HCC (including presumed
HCC), death (including those unrelated to liver dis-
ease), and ascites (Table 1). During the period of ob-
servation, CTP 7, death (including those unrelated
to liver disease), ascites, and HCC were the most com-
mon outcomes experienced by patients.
Among patients with baseline fibrosis, 109 pro-
gressed to cirrhosis at month 24 and a further 69 had
cirrhosis at month 48 (annualized rate of progression
to cirrhosis 9.9%) (Table 2). The observed 8-year and
calculated annualized incidences of each clinical out-
come were three- to four-fold more frequent in the
cirrhosis stratum than in the fibrosis stratum (Table 2).
Once CTP score rose to 7, patients with bridging fi-
brosis at baseline did not differ from those with















All death 49 24 89 29 138 53
Liver-related death 27 5 55 5 82 10
Liver transplantation 30 2 56 2 86 4
Liver-related death or liver transplantation 54 7 103 7 157 14
HCC or presumed HCC 40 35 48 32 88 67
CTP score 7 on two consecutive visits 49 36 121 101 170 137
Variceal hemorrhage 9 5 18 10 27 15
Ascites 34 12 67 23 101 35
Bacterial peritonitis 6 0 3 0 9 0
Encephalopathy 18 8 42 10 60 18
Total* 235 outcomes 122 patients 444 outcomes 207 patients 679 outcomes 329 patients
Each patient could be counted more than once.
*All-cause death þ liver transplantation þ HCC or presumed HCC þ CTP score 7 þ variceal hemorrhage þ ascites þ bacterial peritonitis þ encephalopathy.
Fig. 1. First clinical outcome rates excluding death not related to
liver by stratum and treatment group to year 8.
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cirrhosis at baseline in the rate of subsequent out-
comes. Of 137 study patients with CTP score 7 as
the first clinical outcome, 93 (69%) had a subsequent
clinical outcome after a median time of 11 months;
liver-related death or liver transplantation was the
most frequent event after a CTP score 7, followed
by clinical decompensation and ascites (Table 2). De-
mographic features did not influence outcome rates;
the annualized incidence of outcomes, including pro-
gression to cirrhosis, did not differ between men and
women or between patients younger versus older than
50 years (P > 0.05) (Table 3). There were too few
non-whites or Hispanics to perform meaningful analy-
ses of individual outcomes by ethnic group.
A total of 138 deaths were observed during the
study (i.e., through October 20, 2009), 82 (59%) of
which were liver-related. After the first 1-2 years of ob-
servation, we observed a linear increase in all-cause
death and liver-related death for the entire HALT-C
Trial population (Figure 2A). The cumulative inci-
dence of all deaths and of liver-related deaths or trans-
plantation was higher among patients who had cirrho-
sis compared with patients who did not (Figure 2B).
Following the development of a CTP score 7 (Figure
2C) or a decompensation event (Figure 2D), nearly all
deaths were liver-related.
Laboratory Marker Progression and Outcomes. At
baseline, the prevalence of hypoalbuminemia, throm-
bocytopenia, and hyperbilirubinemia was higher
among patients with cirrhosis than those without cir-
rhosis (Figure 3A,B). The cumulative 8-year incidence
of abnormal levels was higher in the cirrhosis stratum
than the fibrosis stratum for all laboratory markers,
except elevated creatinine, which was comparable in
both strata (Figure 3A,B). During the observation pe-
riod, reductions in albumin and in platelet count
occurred earlier and more frequently than abnormal-
ities in the other laboratory markers measured.
Low platelet count was shown previously to be the
best predictor of overall outcomes in the randomized
phase of the HALT-C Trial (through 3.5 years), irre-
spective of stage of fibrosis.17 With further observa-
tion, we found that the baseline platelet count was
Table 2. Annualized Incidence of Each Clinical Outcome
According to Baseline Stage of Fibrosis (Fibrosis or











Cirrhosis 9.9% — —
CTP score 7 1.4% 5.0% —
Variceal hemorrhage 0.2% 0.9% 1.2 %
Ascites 1.0% 2.9% 12.7%
Encephalopathy 0.5% 1.9% 10.3%
HCC or presumed HCC 1.1% 2.4% 4.5%
All death 1.7% 3.9% 10.0%
All death or liver transplantation 2.2% 5.3% 14.7%
Liver-related death 0.8% 2.6% 8.7%
Liver-related death or liver
transplantation
1.6% 4.2% 14.3%
Any clinical outcome (of all deaths,
HCC, CTP score 7, variceal
hemorrhage, ascites, bacterial
peritonitis, encephalopathy)




1.2% 3.9 % 12.9%
HCC/presumed HCC or decompensation
(variceal hemorrhage, ascites,
bacterial peritonitis, encephalopathy)
2.1% 5.5 % 14.8%
Table 3. Annualized Incidence of Each Clinical Outcome, by Sex and Age
Outcome
Sex Age
Male (n 5 745) Female (n 5 305) <50 Years (n 5 532) 50 Years (n 5 518)
Cirrhosis 9.9% 10.1% 10.5% 9.3%
CTP score 7 2.7% 3.3% 3% 2.8%
Variceal hemorrhage 0.5% 0.6% 0.6% 0.4%
Ascites 1.7% 1.8% 1.9% 1.6%
Encephalopathy 1% 1.3% 1.2% 0.9%
HCC or presumed HCC 1.6% 1.5% 1.3% 1.9%
All death 2.4% 2.6% 2% 2.9%
All death or liver transplantation 3.6% 3.3% 3.1% 3.9%
Liver-related death 1.5% 1.5% 1.4% 1.7%
Liver-related death or liver transplantation 2.8% 2.3% 2.4% 2.9%
Any clinical outcome (of all deaths, HCC,
CTP score 7, variceal hemorrhage, ascites,
bacterial peritonitis, encephalopathy)
4.7% 5.8% 4.7% 5.4%
Decompensation (variceal hemorrhage,
ascites, bacterial peritonitis, encephalopathy)
2.1% 2.8% 2.5% 2.2%
HCC/presumed HCC or decompensation (variceal hemorrhage,
ascites, bacterial peritonitis, encephalopathy)
3.3% 3.7% 3.4% 3.6%
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associated closely with the annual rate of initial clinical
decompensation. The annualized incidence of each
clinical outcome increased over decreasing ranges of
platelet counts from 200,000/mm3 to <100,000/
mm3 (Table 4). For example, patients with a platelet
count <100,000/mm3 were 11-fold more likely to ex-
perience a decompensation event and 14-fold more
likely to die a liver-related death or undergo liver
transplantation, compared with subjects with a baseline
platelet count 200,000/mm3.
Rates of outcomes were also evaluated according to
baseline body mass index, ALT activity, and serum
HCV RNA. The annualized rate of cirrhosis was
8.9% for nonobese subjects versus 11.3% for obese
subjects (P ¼ 0.07); 8.2% for ALT <90 IU/L versus
12.2% for ALT 90 IU/L (P ¼ 0.001); and 11.1%
for HCV RNA <6.5 log10 IU/mL versus 9.0% for
HCV RNA 6.5 log10 IU/mL (P ¼ 0.046). Rate of
any clinical outcome was not associated with baseline
obesity or with ALT activity (P  0.30) but was
associated with lower HCV RNA level (P < 0.0001).
The association of outcomes with HCV RNA level
was not adjusted for stage of fibrosis, which was
strongly and inversely associated with HCV RNA
level (P < 0.0001).
Discussion
Understanding the natural history of advanced hepa-
titis C has been challenging. Limitations in study
design or execution of most, if not all, prior studies
could have led to inaccurate results. No prior study
had the rigor of the histological evaluation of the
HALT-C Trial, in which three liver biopsies were per-
formed and each biopsy was assessed by a team of 11
expert liver histopathologists who were masked to all
patient information.11,12 Additionally, few if any prior
studies had uniform monitoring of patients at regular
intervals and predefined case definitions, whereas
patients in the HALT-C Trial were evaluated every 3-6
months throughout the study, and all outcomes were
reviewed independently by experienced hepatologists.
Furthermore, all patients in the HALT-C Trial had
failed to clear HCV during peginterferon and ribavirin
Fig. 2. Cumulative 8-year incidence of all-cause mortality, liver-related mortality and transplantation, and all-cause mortality and liver trans-
plantation. (A) Entire HALT-C Trial population. (B) Noncirrhotic advanced fibrosis and cirrhosis. (C) CTP score 7 on two consecutive visits. (D)
After onset of decompensated liver disease.
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therapy, whereas in several other studies, progression
was evaluated in patient cohorts, only subsets of whom
were treated, and in whom selection for therapy was
not based on uniform criteria.
For the HALT-C Trial, our hypothesis was that 3.5
years of maintenance, low-dose (90 lg/week) peginter-
feron therapy would retard the progression of chronic
hepatitis C in patients with advanced fibrosis; unfortu-
nately, maintenance therapy was found to be ineffec-
tive. Because clinical outcome rates were either indis-
tinguishable between treated and control patients or
were inconsistently different (higher mortality among
treated patients with noncirrhotic fibrosis and lower
incidence of HCC among treated patients with cirrho-
sis), we pooled the two groups for an analysis of the
rate of progression of chronic hepatitis C. We followed
the combined cohort of >1,000 patients with clinically
compensated advanced fibrosis or cirrhosis, both dur-
ing the randomized (maintenance versus control) phase
and the postrandomization phase for up to 8 years
(median, 5.6 years). Thus, this is the single largest pro-
spective study of clinical and laboratory progression
among patients with chronic hepatitis C and advanced
fibrosis; one of the longest followed cohorts; and the
Fig. 3. Cumulative incidence
of laboratory abnormalities over
time in (A) the fibrosis stratum
and (B) the cirrhosis stratum.
Table 4. Annualized Incidence of Each Clinical Outcome, According to Baseline Platelet Count
Outcome
Platelet Count at Baseline Visit
All (n 5 1,024)<100 (n 5 188) 100 to <150 (n 5 278) 150 to <200 (n 5 282) 200 (n 5 276)
CTP score 7 7.6% 3.4% 1.5% 0.6% 2.9%
Variceal hemorrhage 1.3% 0.4% 0.2% 0.2% 0.5%
Ascites 4.8% 2.2% 0.9% 0.5% 1.8%
Encephalopathy 2.6% 1.3% 0.4% 0.1% 1.0%
HCC or presumed HCC 3.6% 1.9% 1.0% 0.5% 1.6%
All death 5.3% 2.6% 1.9% 1.0% 2.4%
All death or liver transplantation 7.3% 4.0% 2.4% 1.1% 3.4%
Liver-related death 4.3% 1.2% 1.3% 0.3% 1.5%
Liver-related death or liver transplantation 6.4% 2.9% 1.8% 0.5% 2.6%
Any clinical outcome (of all deaths, HCC,
CTP score 7, variceal hemorrhage,
ascites, bacterial peritonitis, encephalopathy)
10.2% 6.1% 3.2% 2.1% 5.0%
Decompensation (variceal hemorrhage, ascites,
bacterial peritonitis, encephalopathy)
6.0% 2.8% 1.1% 0.5% 2.3%
HCC/presumed HCC or decompensation
(variceal hemorrhage, ascites, bacterial
peritonitis, encephalopathy)
7.9% 4.1% 2.0% 1.3% 3.5%
Twenty-six patients with prior splenectomy were excluded.
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only sizable study of an American cohort, most previ-
ous reports having focused on European and Japanese
populations.2,6-9,18
We present the incident rates of clinically meaning-
ful outcomes for patients at three stages of advanced
liver disease: advanced noncirrhotic fibrosis, compen-
sated cirrhosis, and decompensated cirrhosis (CTP
score 7). The observed annual rates of all-cause mor-
tality and liver transplantation were 2.2% in patients
with noncirrhotic fibrosis and 5.3% in those with cir-
rhosis, similar to rates reported in European and Japa-
nese studies. As anticipated, the rate of clinical out-
comes (especially CTP score elevation and variceal
hemorrhage) was higher among patients with cirrhosis
at baseline than those with noncirrhotic fibrosis.
Among patients with noncirrhotic fibrosis, the annual
incidence of initial clinical outcomes ranged from
0.25% per year for variceal hemorrhage to 1.4% per
year for CTP elevation; of note, these outcomes of
end-stage liver disease (including HCC and liver-
related death) occurred in the absence of documented
cirrhosis at entry into the HALT-C Trial, although we
cannot exclude the possibility that some patients may
have been understaged at entry or progressed to cirrho-
sis by the time an outcome developed. For patients
with histological cirrhosis at entry into the HALT-C
Trial, the annual incidence of clinical outcomes ranged
from 0.9% per year for variceal hemorrhage to 5.0%
per year for CTP score elevation. Among individual
clinical outcomes, the most frequent initial decompen-
sation event was an increase in CTP score to 7.
Once the CTP score became elevated, the incidence of
second clinical events was indistinguishable between
subjects in the fibrosis and cirrhosis strata. Thereafter,
morbidity and mortality rates increased substantially,
confirming the value of a rise in CTP score as an omi-
nous prognostic sign.
Findings among HALT-C Trial patients with noncir-
rhotic fibrosis and cirrhosis can be compared with esti-
mates drawn from other studies. Based on the readings
from three liver biopsies over 4 years, HALT-C Trial
patients with bridging fibrosis had an annual incidence
of cirrhosis of 9.9% per year, a rate that differed little
with sex or age and that was comparable to an esti-
mated annual incidence of 11.5% derived from a
meta-analysis conducted in 2007.19 Our directly
observed, empirical results differ from those in a recent
modeling projection in which an approximate four-
fold difference in progression to cirrhosis was assumed
between younger women and older men.20 A potential
explanation for the lack of an effect of sex and age on
disease progression in our study may be that once
advanced liver disease has developed, age and sex may
no longer influence disease progression. In a recent
systematic overview of outcomes among patients with
HCV-related compensated cirrhosis, information was
summarized from 13 cohort studies: eight from West-
ern Europe, four from Japan, and one from the United
States.21 The 5.3% per year rate of death or transplan-
tation in patients with cirrhosis from the current study
is well within the reported range of 2.7%-6.7%, and
the 2.4% per year rate of HCC is at the lower end of
the reported range of 1.8%-7.1%. For HCC, the high-
est reported rates came from Japan.
In addition to studying the occurrence of clinical
events, we monitored the development of laboratory
abnormalities that are associated with deteriorating
liver function. Hypoalbuminemia and thrombocytope-
nia were common at study entry, but their occurrence
rates and those of other laboratory abnormalities were
relatively linear over the 8 years of observation. The
MELD score, which is based on serum bilirubin, creat-
inine, and international normalized ratio/prothrombin
time, determines priority for liver transplantation in
the United States, with a minimum score of 15 for a
patient to be considered for transplantation. Among
patients with fibrosis, the rate of development of a
MELD score 15 was low; the 8-year cumulative inci-
dence was 8%. Among patients with cirrhosis, the
8-year cumulative incidence was higher (21%).
These calculations do not include the MELD score
upgrade for patients with HCC, who constituted
nearly half of the patients in the HALT-C Trial cohort
who underwent transplantation. We demonstrated pre-
viously that thrombocytopenia was a strong predictor
of progressive liver disease,17 which was confirmed in
this analysis with longer follow-up. Outcome rates var-
ied many fold with progressively lower platelet counts
(Table 4). Given the high rate of clinical events among
patients with thrombocytopenia, it is particularly con-
cerning that thrombocytopenia developed among
40% of patients with fibrosis and 80% of patients
with cirrhosis during the 8 years of observation (Figure
3). Such information could be especially useful in pre-
dicting prognosis in the absence of liver biopsy.
The major strength of this report is that it repre-
sents the largest prospective study of the progression of
chronic hepatitis C and one of the only such studies
conducted in the United States. Although derived
from a large, multicenter study, these results would
not necessarily apply to all patients with advanced hep-
atitis C. Study patients had to meet the stringent
inclusion and exclusion criteria for the clinical trial.
They could not have other causes for liver diseases,
HEPATOLOGY, Vol. 54, No. 2, 2011 DIENSTAG ET AL. 403
they were not injection drug users or excessive alcohol
consumers at the time of enrollment, they demon-
strated the motivation and ability to tolerate long-term
peginterferon therapy, and they had failed to clear
HCV on standard doses of peginterferon and ribavirin.
Although patients in the HALT-C Trial might be a
nonrepresentative sample of current patients with
HCV infection and histologically advanced liver dis-
ease, they are fairly representative of the types of
patients clinicians will encounter increasingly. With
the wide availability and application of antiviral ther-
apy, many patients with advanced fibrosis who will be
monitored clinically are those who have already failed
a course of antiviral therapy and who do not have
good treatment options for prevention of liver disease
progression. In an era of antiviral therapy, studies of
the true, intervention-free natural history of chronic
hepatitis C can no longer be performed, and our data,
reflective of a more relevant patient demographic, will
provide clinical guidance most applicable to the
emerging patient population.
The other strengths of this report are the rigor of
data collection and the breadth of the predefined out-
comes. All patients met clearly defined enrollment cri-
teria, including a biopsy that demonstrated histologi-
cally advanced liver disease and that excluded other
causes of severe disease. We are not aware of reports of
other patient populations in which the progression of
disease was documented for the three groups of
patients included in the current study: those with pre-
cirrhotic fibrosis, compensated cirrhosis, and early
decompensated liver disease. Serial liver biopsies were
obtained from the large majority of patients and read
centrally by expert histopathologists. Patients attended
protocol-driven, regularly scheduled appointments,
during which the presence and absence of each clinical
outcome was determined. Finally, all clinical outcomes
were confirmed by an independent panel of study
hepatologists.
In conclusion, we have documented the rate of de-
velopment of histologically defined cirrhosis in patients
with chronic hepatitis C and advanced fibrosis as well
as the incidence of clinically meaningful outcomes
among patients with noncirrhotic fibrosis, cirrhosis,
and early decompensated liver disease. Moreover, we
demonstrated the rates at which laboratory abnormal-
ities developed as well as the relationship of platelet
count to outcome rate. Such data should be helpful in
guiding physicians who follow patients with histologi-
cally advanced chronic hepatitis C, preparing them for
what outcomes to anticipate and at what annual
incidence.
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